N1-(cyclopropyImethyI)-4-methoxybenzene-1,2-diamine | 1257327-82-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: N1-(cyclopropyImethyI)-4-methoxybenzene-1,2-diamine
• 英文别名: N1-(cyclopropylmethyl)-4-methoxybenzene-1,2-diamine；1-N-(cyclopropylmethyl)-4-methoxybenzene-1,2-diamine
• CAS: 1257327-82-4
• 化学式: C₁₁H₁₆N₂O
• mdl: MFCD20669254
• 分子量: 192.261
• InChiKey: IYVDPSYYYFFCKC-UHFFFAOYSA-N

物化性质

• 沸点：
  358.4±32.0 °C(Predicted)
• 密度：
  1.169±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  47.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N1-(cyclopropyImethyI)-4-methoxybenzene-1,2-diamine 在 正丁基锂 、 氯化亚砜 、 甲烷磺酸 、 三溴化硼 、 caesium carbonate 、 亚硝酸异戊酯 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 异丁酰胺 、 溶剂黄146 为溶剂， 反应 18.55h， 生成 2-(2-{[4-chloro-1-(cyclopropylmethyl)-1H-benzotriazol-5-yl]oxy}pyridin-3-yl)propan-2-ol
  参考文献：
  名称：

  [EN] ETHER BENZOTRIAZOLE DERIVATIVES
  [FR] DÉRIVÉS D'ÉTHER DE BENZOTRIAZOLE

  摘要：

  本发明涉及醚苯并三唑衍生物，其是代谢型谷氨酸受体的增强剂，特别是mGluR2受体，并且在治疗或预防与谷氨酸功能障碍相关的神经系统和精神疾病以及代谢型谷氨酸受体参与的疾病中具有用途。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗代谢型谷氨酸受体参与的疾病中使用这些化合物和组合物。

  公开号：

  WO2011022312A1
• 作为产物：
  描述：

  2-硝基-4-甲氧基苯胺 在 3percent Pt/0.6percent VG/C 氢气 、 溶剂黄146 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 10.0~20.0 ℃ 、275.8 kPa 条件下， 反应 7.58h， 生成 N1-(cyclopropyImethyI)-4-methoxybenzene-1,2-diamine
  参考文献：
  名称：

  ETHER BENZOTRIAZOLE DERIVATIVES

  摘要：

  本发明涉及乙醚苯并三唑衍生物，它们是代谢型谷氨酸受体的增效剂，特别是mGluR2受体，对治疗或预防与谷氨酸功能障碍相关的神经系统和精神疾病以及代谢型谷氨酸受体参与的疾病具有用处。该发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗代谢型谷氨酸受体参与的疾病中的使用。

  公开号：

  US20120135977A1

文献信息

• [EN] AMINOMETHYL BIARYL BENZOTRIAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS D'AMINOMÉTHYL-BIARYL-BENZOTRIAZOLE
  申请人：MERCK SHARP & DOHME

  公开号：WO2012151136A1

  公开（公告）日：2012-11-08

  The present invention is directed to aminomethyl biaryl benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

  本发明涉及氨甲基联苯基苯并三唑衍生物，它们是代谢型谷氨酸受体的增强剂，特别是mGluR2受体，适用于治疗或预防与谷氨酸功能障碍相关的神经系统和精神疾病，以及代谢型谷氨酸受体参与的疾病。该发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗代谢型谷氨酸受体参与的疾病中的用途。
• [EN] BIARYL BENZOTRIAZOLE DERIVATIVES<br/>[FR] DERIVES DE BENZOTRIAZOLE BIARYLE
  申请人：MERCK SHARP & DOHME

  公开号：WO2010141360A1

  公开（公告）日：2010-12-09

  The present invention is directed to biaryl benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

  本发明涉及生物芳基苯并三唑衍生物，其是代谢型谷氨酸受体的增强剂，特别是mGluR2受体，并且在治疗或预防与谷氨酸功能障碍有关的神经和精神障碍以及代谢型谷氨酸受体参与的疾病方面有用。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗代谢型谷氨酸受体参与的疾病方面使用这些化合物和组合物。
• ETHER BENZOTRIAZOLE DERIVATIVES
  申请人：Beshore Douglas C.

  公开号：US20120135977A1

  公开（公告）日：2012-05-31

  The present invention is directed to ether benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

  本发明涉及乙醚苯并三唑衍生物，它们是代谢型谷氨酸受体的增效剂，特别是mGluR2受体，对治疗或预防与谷氨酸功能障碍相关的神经系统和精神疾病以及代谢型谷氨酸受体参与的疾病具有用处。该发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗代谢型谷氨酸受体参与的疾病中的使用。
• [EN] HYDROXYMETHYL BIARYL BENZOTRIAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS HYDROXYMÉTHYLE BIARYLE BENZOTRIAZOLES
  申请人：MERCK SHARP & DOHME

  公开号：WO2012151140A1

  公开（公告）日：2012-11-08

  The present invention is directed to hydroxymethyl biaryl benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

  本发明涉及羟甲基联苯苯并三唑衍生物，其是代谢型谷氨酸受体的增强剂，特别是mGluR2受体，可用于治疗或预防与谷氨酸功能障碍相关的神经系统和精神疾病，以及代谢型谷氨酸受体参与的疾病。该发明还涉及含有这些化合物的药物组合物，以及这些化合物和组合物在预防或治疗代谢型谷氨酸受体参与的疾病中的用途。
• [EN] CYCLOHEXENE BENZOTRIAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS DE CYCLOHEXÈNE-BENZOTRIAZOLE
  申请人：MERCK SHARP & DOHME

  公开号：WO2012151138A1

  公开（公告）日：2012-11-08

  The present invention is directed to cyclohexene benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

  本发明涉及环己烯苯并三唑衍生物，这些衍生物是代谢型谷氨酸受体的增强剂，特别是mGluR2受体，可用于治疗或预防与谷氨酸功能障碍有关的神经和精神障碍，以及代谷氨酸受体参与的疾病。本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗代谷氨酸受体参与的疾病中的用途。